GRAIL, Inc. Common Stock When Issued (GRAL)
| Market Cap | 468.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 31.10M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,810,814 |
| Open | 15.00 |
| Previous Close | 14.96 |
| Day's Range | 14.97 - 15.77 |
| 52-Week Range | 12.51 - 23.36 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 15, 2024 |
About GRAL
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2... [Read more]
News
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitaliz...
Grail's shares fall in Nasdaq debut after spin-off from Illumina
Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina.
Grail expected to be first FDA-approved multi-cancer test, says CEO Bob Ragusa
Grail CEO Bob Ragusa joins CNBC's 'Squawk Box' to discuss the company's debut on the Nasdaq, how Grail is innovating early cancer detection, and more.
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers a...
GRAIL to Begin Trading on the Nasdaq Stock Exchange
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC) will be listed and commence regular-way trading on the Nasdaq as of tomorrow, June 25, 2024.